AYA.AX down 8.29% to A$3.87 Artrya Limited (ASX) market closed 28 Jan 2026: AI stocks outlook
AYA.AX stock closed the session at A$3.87, down 8.29% on 28 Jan 2026 after a volatile day that saw a high of A$4.12 and low of A$3.79. Traders reacted to a mix of technical overbought signals and company fundamentals. Artrya Limited (AYA.AX) remains a small-cap Australian medtech focused on AI coronary disease detection. We summarise price action, financial metrics, technicals, Meyka AI grading and a model forecast to frame the near-term AI stocks outlook for AYA.AX stock.
AYA.AX stock: Market close snapshot
AYA.AX stock finished at A$3.87 on the ASX with 572,721 shares traded, below the 30-day average volume of 822,664. The stock opened at A$4.08, hit a session high of A$4.12 and a low of A$3.79. One-day change was -0.35 (down 8.29%).
Year range sits between A$0.56 and A$5.24, giving the stock a market capitalisation of A$463,478,800.00 and shares outstanding of 113,320,000. Short-term momentum shows an RSI of 70.89, suggesting near-term overbought conditions for this AI healthcare name.
Business model and AI positioning
Artrya Limited (AYA.AX) sells Salix, a cloud software that uses artificial intelligence to detect coronary artery disease from CT angiography. The company is positioned in the Healthcare sector and the Medical – Healthcare Information Services industry, targeting diagnostic automation opportunities.
AYA.AX stock sits in a growth niche within AI-driven medical imaging. Progress on clinical adoption, regulatory clearances, and hospital contracts will be the main operational drivers that connect product milestones to revenue growth.
Financials and valuation metrics
Artrya reports an EPS of -0.18 and a trailing PE of -22.72, reflecting negative earnings. Key balance measures include a strong current ratio of 8.27 and cash per share of 0.11. The price-to-book ratio is 19.80, showing the market currently prices high growth expectations relative to book value.
Profitability and cashflow remain weak: operating cash flow per share is -0.14 and free cash flow per share is -0.14. Research and development intensity is high at 197.50% of revenue, consistent with an AI medtech in scale-up mode.
Technical view, liquidity and sector context
Technically, AYA.AX shows short-term strength but signs of pullback risk. RSI at 70.89 and MFI 82.92 indicate overbought conditions. The 50-day average price is A$3.95 and the 200-day average is A$2.20, with recent outperformance versus the longer trend.
In the Australian Healthcare sector, large-cap peers show muted 6-month gains of about 9.09%, making Artrya a higher-volatility small-cap alternative inside the sector. Liquidity is moderate; average daily volume of 822,664 supports trading but can amplify moves on news.
Meyka AI grade and model forecast
Meyka AI rates AYA.AX with a score of 59.29 out of 100 (C+, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are informational and not financial advice.
Meyka AI’s forecast model projects a monthly target of A$4.06, a quarterly target of A$6.10, and a 12-month target of A$7.30. Compared with the current price of A$3.87, the 12-month projection implies an upside of 88.73%. Forecasts are model-based projections and not guarantees.
Risks and catalysts for AYA.AX stock
Key upside catalysts include new hospital contracts, positive clinical study results, regulatory approvals, and revenue scaling that narrow losses. AYA.AX stock would also benefit from broader AI health funding or strategic partnerships.
Primary risks are continued negative earnings, high R&D spend, slow adoption by health systems, and valuation compression if growth disappoints. Watch earnings announcement scheduled for 24 Feb 2026 for revenue and guidance updates.
Final Thoughts
AYA.AX stock closed the ASX session at A$3.87 on 28 Jan 2026 after a decline of 8.29%, reflecting a mix of overbought technical signals and ongoing fundamental risk for this AI medtech. Financials show negative EPS (-0.18) and weak cash generation, balanced by a solid liquidity buffer (current ratio 8.27) and a clear product-market proposition with Salix. Meyka AI’s forecast model projects a 12-month target of A$7.30, implying a potential upside of 88.73% versus the current price. That projection assumes successful clinical adoption and revenue growth; failures on those fronts would materially compress expectations. For investors focused on AI stocks, Artrya offers high reward potential paired with high execution risk. Monitor the 24 Feb 2026 earnings release, clinical milestones, and any hospital contract announcements. Forecasts are model-based projections and not guarantees.
FAQs
What drove AYA.AX stock lower today?
AYA.AX stock fell 8.29% on 28 Jan 2026 after intraday profit-taking amid overbought technical indicators (RSI 70.89) and ongoing negative earnings. Traders trimmed positions ahead of the 24 Feb 2026 earnings announcement.
What is Meyka AI’s forecast for AYA.AX stock?
Meyka AI’s forecast model projects AYA.AX at A$7.30 in 12 months, implying roughly 88.73% upside from A$3.87. Forecasts are model-based projections and not guarantees.
Is AYA.AX stock a profitable company today?
No. Artrya reports a trailing EPS of -0.18 and negative operating cash flow per share. The company is investing heavily in R&D as it scales Salix in clinical markets.
What are the main risks for AYA.AX stock?
Main risks for AYA.AX stock include slow clinical adoption, persistent losses, high R&D burn, and valuation compression if revenue growth lags. Regulatory or contract setbacks would also weigh on the share price.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
